Structural insights into the molecular mechanism of high-level ceftazidime–avibactam resistance conferred by CMY-185
mBio · 14.02.2024 · 15 (2)
DOI: 10.1128/mbio.02874-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift mBio, erschienen am 14.02.2024. Verfasst von Akito Kawai und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Fujita Health University School of Medicine, Toyoake, Aichi, Japan. Hauptthemen laut MEDLINE: Ceftazidime, Anti-Bacterial Agents, Azabicyclo Compounds. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, HHS | NIH | National Institute of Allergy and Infectious Diseases, MEXT | Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Ceftazidime-avibactam has a broad spectrum of activity against multidrug-resistant Gram-negative bacteria including carbapenem-resistant Enterobacterales including strains with or without production of serine carbapenemases. After its launch, emergence of ceftazidime-avibactam-resistant strains that produce mutated β-lactamases capable of efficiently hydrolyzing ceftazidime or impairing avibactam inhibition are increasingly reported. Furthermore, cross-resistance towards cefiderocol, the latest cephalosporin in clinical use, has been observed in some instances. Here, we clearly demonstrate the functional role of the substituted residues in CMY-185, a four amino-acid variant of CMY-2 identified in a patient treated with ceftazidime-avibactam, for high-level resistance to this agent and low-level resistance to cefiderocol. These findings provide structural insights into how β-lactamases may incrementally alter their structures to escape multiple advanced β-lactam agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
- Center for Infectious Disease Research, Fujita Health University, Toyoake, Aichi, Japan.
- Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
- Division of Pathology/Lab Medicine, Department of Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
ORCID-Profile: Akito Kawai, William C Shropshire, Masahiro Suzuki, Jovan Borjan, Samuel L Aitken, Micah M Bhatti, Ryan K Shields, Samuel A Shelburne, Yohei Doi
Förderung
- NIAID NIH HHS
- HHS | NIH | National Institute of Allergy and Infectious Diseases
- MEXT | Japan Society for the Promotion of Science
- Takeda Science Foundation
Zitieren
APA
Kawai, A., Shropshire, W. C., Suzuki, M., Borjan, J., Aitken, S. L., Bachman, W. C., McElheny, C. L., Bhatti, M. M., Shields, R. K., Shelburne, S. A., & Doi, Y. (2024). Structural insights into the molecular mechanism of high-level ceftazidime–avibactam resistance conferred by CMY-185. mBio, 15(2). https://doi.org/10.1128/mbio.02874-23
Vancouver
Kawai A, Shropshire WC, Suzuki M, Borjan J, Aitken SL, Bachman WC, et al. Structural insights into the molecular mechanism of high-level ceftazidime–avibactam resistance conferred by CMY-185. mBio. 2024;15(2). doi:10.1128/mbio.02874-23
BibTeX
@article{Kawai2024,
author = {Kawai, Akito and Shropshire, William C and Suzuki, Masahiro and Borjan, Jovan and Aitken, Samuel L and Bachman, William C and McElheny, Christi L and Bhatti, Micah M and Shields, Ryan K and Shelburne, Samuel A and Doi, Yohei},
title = {Structural insights into the molecular mechanism of high-level ceftazidime–avibactam resistance conferred by CMY-185},
journal = {mBio},
year = {2024},
volume = {15},
number = {2},
doi = {10.1128/mbio.02874-23}
}
EUVIMED